Tag Annaliesa Anderson

Clinical Trials, News

Positive top-line results from Phase 3 study of ABRYSVO® in adults aged 18 to 59 at increased risk for RSV Disease

Pfizer announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating a single dose of ABRYSVO versus placebo in adults 18 to 59 years…

April 9, 2024

New Treatments, News

FDA approves PENBRAYA™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents.

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal…

October 20, 2023